Skip to main content
PLOS One logoLink to PLOS One
. 2024 Feb 23;19(2):e0296671. doi: 10.1371/journal.pone.0296671

MiR-155 promotes compensatory lung growth by inhibiting JARID2 activation of CD34+ endothelial progenitor cells

Li Zhao 1,#, Jing Peng 1,#, Li Zhuang 2, Zhiling Yan 3, Fei Liao 4, Yifan Wang 1, Shihao Shao 1, Weiwei Wang 5,*
Editor: Zhijie Xu6
PMCID: PMC10890733  PMID: 38394221

Abstract

Bone marrow-derived CD34-positive (CD34+) endothelial progenitor cells (EPCs) has unique functions in the mechanism of compensatory lung growth (CLG). The content of this study is mainly to describe the effect of microRNA (miR)-155 in the mechanisms of EPCs and CLG. Our study found that transfection of miR-155 mimic could promote EPC proliferation, migration and tube formation, while transfection of miR-155 inhibitor had the opposite effect. It was also found that transfection of pc-JARID2 inhibited EPC proliferation, migration and tube formation, while transfection of si-JARID2 had the opposite effect. miR-155 can target and negatively regulate JARID2 expression. Overexpression of JARID2 weakened the promoting effects of miR-155 mimic on EPC proliferation, migration, and tubular formation, while silencing JARID2 weakened the inhibitory effects of miR-155 inhibitors on EPC proliferation, migration, and tubular formation. Transplantation of EPCs transfected with miR-155 mimic into the left lung model effectively increased lung volume, total alveolar number, diaphragm surface area, and lung endothelial cell number, while transplantation of EPCs co-transfected with miR-155 mimic and pc-JARID2 reversed this phenomenon. Overall, we found that miR-155 activates CD34+ EPC by targeting negative regulation of JARID2 and promotes CLG.

1 Introduction

In most mammals, the removal of one lung leads to rapid growth of the remaining lung mass is called compensatory lung growth (CLG) [1,2]. According to a large number of literatures, this phenomenon has occurred in mice [3], rats [4], pigs [5], dogs [6], rabbits [7] and ferrets [8], the mechanism for the occurrence of CLG is still puzzling. CLG effect triggered after pneumonectomy can lead to increased lung volume and alveolar number, and they showed that it is a key mechanism for neovascularization [9]. It has recently been shown that within 3 weeks after pneumonectomy, the number of endothelial cells in the lungs of mice increased 3.2 times and the number of CD34+ endothelial cells increased 7.3 times in time. Blood-derived CD34+ endothelial progenitor cells (EPCs) become resident endothelial cells during CLG and contribute to pulmonary angiogenesis [10]. Therefore, we speculate that the mechanism of CLG may be related to the development of EPCs.

EPCs are bone marrow stem cells, which have the ability to differentiate into mature cells, promote the formation of new blood vessels, and maintain the integrity of blood vessels [11,12]. Studies have shown that microRNAs (miRNAs) can regulate EPCs proliferation, migration and angiogenesis [13,14]. miRNAs are relatively small in molecular weight and are 18–23 nucleotides in length. They can silence or degrade mRNA, and then metabolize and degrade mRNA in biological processes. regulation of death [15]. After consulting the literature, we know that MiR-155 is inextricably linked with the proliferation and migration of CD34+ cells. In the study of inducing adipose-derived stem cells (ASCs) to differentiate into endothelial cells, miR-155 can mediate the occurrence of endothelial differentiation of CD34+ ASCs [16]. To explore whether miR-155 can make CD34+ chronic myeloid leukemia (CML) cells eliminate the growth inhibition of TGF-β1 and signal transduction of bone morphogenetic protein (BMP), miR-155 was overexpressed, which significantly promoted the proliferation rate of CD34+ CML cells [17]. We speculate that the proliferation of CD34+ endothelial cells in CLG can also be regulated by miR-155.

MiRNA regulates gene expression at the posttranscriptional level mainly through complementary pairing with target mRNA [18], and software prediction and literature showed that JARID2 and miR-155 had a targeted binding relationship [1922]. JARID2 is a member of the Jumonji family of proteins that have been shown to regulate cell proliferation and migration [23]. In primary myofibrosis (PMF) studies, JARID2 silencing has been shown to promote proliferation and differentiation of normal CD34+ cells [19]. In addition, in the study of the effects of JARID2 on trophoblast cell viability and invasion, it was also found that JARID2 silencing could significantly reduce the cell viability, migration and invasion of HTR8/SVneo cells [23]. There are also studies that show that silencing JARID2 can inhibit the progression of bladder cancer [24]. Hence, we speculated that miR-155 regulates CD34+ endothelial cells by mediating JARID2.

Here, we isolated EPCs from mouse lung tissue and evaluated the state of CD34+ EPCs by overexpressing or fsressing miR-155, amplifying or silencing JARID2, and simultaneously overexpressing/amplifying or suppressing/silencing miR-155 and JARID2. Finally, we assessed the effect of EPCs transplantation via the tail vein on CLG in a pneumonectomy model mouse.

2 Materials and methods

2.1 Separation and identification of EPCs

After the mice were anesthetized by intraperitoneal injection of 120–400 mg/kg Avertin, the lungs were excised in the airways to reduce additional lung airways, with the lung tissue cut into 1 cubic centimeter pieces and treated with collagenase (1 mg/mL; Sigma-Aldrich, St. Louis, MO, USA) and dispersed enzyme solution (2.5 U/mL; Sigma-Aldrich, St. Louis, MO, USA). The methods of isolating cells were performed according to Van Beijnum et al. [25] with minor modifications. Briefly, mononuclear cells were isolated by Ficoll gradient centrifugation (GE Healthcare, Piscataway, NJ, USA). Cells screened for CD34+ with EasySep Immunomagnetic Bead Human CD34 Cell Positive Selection Reagent (STEMCELL Technologies, Vancouver, BC, Canada) were seeded with fibronectin (10 μg/ml, BD Biosciences, San Jose, CA, USA) in EGM-2 medium (Lonza Group Ltd., Basel, Switzerland) containing 10% FBS. After 48 hours, the unadherent cells and cell fragments were removed and the adherent cell medium was replaced, and the fresh medium was replaced daily. After 7 days, adherent cells were screened based on EPC surface markers.

A total of 1×105 well-grown cells up to five passages were incubated with 1% BSA diluted antibody CD34-FITC (100 μL/tube, BD Biosciences, San Jose, CA), incubated on ice for 40 min in the dark. PBS rinses, centrifugation discards the supernatant, resuspends with PBS and then analyzes on the flow cytometer. Cells within 5 passages in a good growth state were collected and mixed with DiI-AC-LDL (10 μg/mL; BT-902, Bioquote, York, UK), incubated at 37°C for 1 hour, fixed with 4% paraformaldehyde, incubated for 1 hour at 37°C, and washed 3 times with PBS and then 1 time with distilled water. DAPI (ab228549, Abcam, UK) was added to the stained specimen, 50% buffered glycerol was added to mount the specimen, and fluorescence confocal microscopy was performed (Leica Microsystems GmbH, Germany).

2.2 Vector construction and cell transfection

JARID2 expression vector (pc-JARID2) inserted with the JARID2-coding sequence (CDS) for JARID overexpression. small interfering RNA JARID2 (si-JARID2), miR-155 mimics, inhibitor, and the corresponding control were synthesized by GenePharma (Shanghai, China). Transfection was performed according to the Lipofectam 2000 transfection kit (11668–500, Invitrogen, USA).

2.3 CCK-8 analysis of cell proliferation

Cells (2×106) inoculated into 96-well plates and an equal amount of PBS solution was added to each well, and after the cells grew up against the wall, the supernatant was discarded and new medium was added. The plates were incubated at 37°C, 5% CO2 for 2 day. After that, adding CCK-8 solution (Dojindo Laboratories company, Japan) to the sample and modulating the enzyme label, the absorbance was measured at 450 nm wavelength.

2.4 Transwell assay of cell migration

The cells were inoculated at the top of a polycarbonate Transwell chamber without matrix glue, and the cells were cultured in serum-free medium. We added serum-containing culture medium into the bottom chamber. Then stained the fixed cells with crystal violet (Beyotime Institute of Biotechnology, Haimen, China), and finally observed and counted microscopically.

2.5 Tube formation experiment

Matrigel (BD Biosciences, San Jose, CA) was seeded for up to 1 hour at 37°C to form reconstituted basement membranes. Transfected EPCs (2 × 104 cells /100 μL) were harvested, seeded on Matrigels, and incubated for 6 hours at 37°C. We examined the lumen structure under an inverted light microscope (IRB20, Microscope World, Carlsbad, CA, USA).

2.6 RT-qPCR

TRIzol RNA extraction kit (15596–018, Invitrogen, Madison, MI, USA) is served by extracting the total RNA from the collected cells and tissues. Then, the first strand of cDNA was assembled using the total RNA of the sample as a template, and the cDNA obtained in is used as a template for qPCR amplification, and subsequent PCR process was completed using cDNA, as well as U6 and GAPDH as the internal reference, according to the instructions of SYBR Green qPCR kit. Then, the expression levels of cells and tissues were calculated using the 2–ΔΔCT method.

2.7 Western blotting

Proteins were extracted using RIPA buffers, followed by BCA protein kits measures protein concentration. The protein was isolated by electrophoresis of sodium dodecyl sulphate-polyacrylamide gel and transferred to PVDF membrane. Then the PVDF membrane was incubated with primary antibody (Abcam, UK) including anti-JARID2 (ab184152,1:10000), anti-VEGFA (ab52917,1:10000), anti-MMP-2 (ab92536, 1:2500), and anti-GAPDH (ab181602,1:10000) and a HRP-conjugated anti-goat anti-rabbit IgG H&L secondary antibody (ab205718, 1:2000). After incubation, the membranes were finally assessed for expression semi-quantitatively by enhanced chemiluminescence (ECL) (Millipore, Billerica, MA, U. S. A.) chromogenic and gel imaging.

2.8 Animal model construction

In this study, C57BL/6 8-week-old mouse (Vital River Laboratory, Beijing, China) were picked out for the experiment. Mice were anesthetized by intraperitoneal injection of 120–400 mg/kg Avertin (Sigma, St. Louis, MO). After the left chest of mice was cleaned with an electric razor and disinfected with iodor, a ventral anterior axillary incision was made vertically from the left axilla to the left rib margin. After finding the left lung through the incision, the hilum was transected with tweezers and microdissection scissors. The incision was closed with PDS sutures. The mice were observed for at least 48 hours after surgery, and buprenorphene (0.1 mg/kg) was given every 8 hours for analgesia to alleviate the pain caused by surgery.

Three days after the animal model was established, the mouse were randomly assigned to (A) NC group (1 × 106 EPCs were simply transplanted by tail vein injection); (B) miR-155 mimic + pc-NC group (EPCs transfected with miR-155 mimic and negative control JARID2); (C) NC mimic + pc-JARID2 group (EPCs transfected with negative control miR-155 mimic and pc-JARID2); (D) miR-155 mimic + pc-JARID2 group (EPCs overexpressing both miR-155 and JARID2 were transfected). The mice were sacrificed by cervical dislocation 4 days (The most active lung growth spot) after transplantation, and right lung tissue was removed for subsequent experiments. Animal studies were reviewed and approved by the Ethics Committee of Yunnan Cancer Hospital (SLKYLX202177), and in accordance with the National Guide for the Care and Use of Laboratory Animals.

2.9 Dual-luciferase reporter assay

The wild type JARID2 vector (WT) was constructed by cloning the JARID2 3 ’ -UTR fragment containing the miR-155 binding site into the vector. An empty vector control, mutant JARID2vector (MUT), was also prepared. The reporter gene plasmid JARID2 WT and JARID2 MUT together with the transcription factor expression plasmid miR-155 mimic and the negative control (NC mimic) were transfected (Lipofectamine; 2000Invitrogen, Carlsbad, CA, USA) two days later. A dual luciferase reporter assay kit was (Promega, USA) used for analysis.

2.10 Lung volumetric and morphometric analysis

The mice were euthanized 4 days after the EPCs were transplanted and a water replacement procedure (Scherle) was performed to measure the remaining right lung volume (normalized). The specimens were treated with 10% formalin and 70% ethanol and embedded in paraffin for histological analysis. The lung specimens were stained with hematoxylin and eosin (H&E) on the fourth day and the sections were sectioned for morphometric analysis [26,27]. The counts of points and intersections (on the overlaid 42-point grid) on each lung field (greater than 40) were observed for each slice at appropriate multiples to determine parameters such as lung parenchyma volume, total number of alveoli, and septal surface area.

2.11 Immunofluorescence analysis

The previously embedded sections were dewaxed with xylene and hydrated in gradient ethanol. Epitope repair was then performed using a pressurized chamber at 120°C (Decloaking Chamber, Biocare Medical, Pacheco, California) by citrate solution (Vector Laboratories, Burlingame, CA)-based implementation. The slides were cleaned with PBST and incubated in a closed solution for 30 minutes. Incubate overnight with primary antibody (Ki67, ERG) at 4°C. The next day, the slides were cleaned with PBST and incubated in Alexa Fluor-coupled IgG H&L (ab450073, Abcam, UK). After DAPI re-dyeing, PBST was washed, dried and fixed.

The lung sections of each group were observed with a fluorescence confocal microscope, and four random fields of the entire right lung were sampled for cell counting at 10 times magnification for each sample. Image J for counting positive cells, and the proliferating cells were manually counted and labeled based on the double staining of ERG and Ki67. Total endothelial cell were used for normalization calculation.

2.12 Statistical analysis

SPSS 21.0 software (IBM Corporation, Armonk, NY, USA) was served analyze the data. Datas are given in mean±SD. In statistical comparison, students’ t-test was used when there were only two groups of differences between groups. Moreover, one-way ANOVA was served for multiple groups. P<0.05 indicates statistical significance.

3 Results

3.1 Cultivation and identification of EPCs

EPCs clusters and adherent cells formed fusiform structures after 3 and 7 days of culture, respectively (Fig 1A). After observing the results of immunofluorescence, we knew that DiI-ac LDL (red) could be absorbed by EPCs, making EPCs pink (Fig 1B). After screening with CD34+ immunomagnetic beads, flow cytometric analysis to determine the identity of the EPCs showed that the CD34 positivity of the isolated cells was 87.4%, indicating that the isolated monocytes were CD34+ EPCs (Fig 1C).

Fig 1. Cultivation and identification of EPCs.

Fig 1

(A)EPCs morphology under an inverted light microscope (Days 3 and 7); (B) DiI-ac-LDL staining; (C)Flow cytometry analysis showing the positive expression of CD34 on EPCs and the positive expression of CD34 after immunomagnetic bead sorting.

3.2 Effect of miR-155 on EPCs proliferation, migration, and tube formation

After evaluation by RT-qPCR, the quantitative data showed that miR-155 was significantly upregulated in the mimics group and downregulated in the inhibitor group (Fig 2A). Moreover, the level of JARID2 showed a clear downward trend in the miR-155 mimics group and upregulated in the inhibitor group (Fig 2B). These results indicate that in EPCs, miR-155 mimics and inhibitors can increase or decrease the level of miR-155, respectively, and have the above-mentioned opposite regulatory trends for JARID2.

Fig 2. Effect of miR-155 on EPCs proliferation, migration, and tube formation.

Fig 2

(A) The expression of miR-155 was detected by RT-qPCR; (B) The expression level of JARID2 mRNA was detected by RT-qPCR; (C) Cell proliferation activity was detected by CCK-8; (D) Cell migration level was detected by Transwell; (E) Detection of cell tube formation ability; (F) The level of Ang-1 secretion was detected by ELISA; (G) The expression levels of VEGF and MMP-2 protein were detected by Western blot. *P<0.05, **P<0.01, and ***P<0.001 vs. NC group; ##P<0.01, and ###P<0.001.

By analyzing the resulting data from CCK-8, Transwell, and tube-forming assays, we learned that the miR-155 mimic group showed increased viability, migration, and tube-forming ability of EPCs, while that miR-155 inhibitor group show the opposite result (Fig 2C–2E). Moreover, the ELISA and Western blot detection results for angiogenesis-related factors showed that the secretion level of Ang-1 and the levels of VEGF and MMP-2 showed an upward trend in the mimics group but decreased in the inhibitor group (Fig 2F and 2G). It is known from that experimental data that upregulation of miR-155 can promote the development of EPCs, as well as the expression levels of the angiogenesis-related factors Ang-1, VEGF and MMP-2.

3.3 Effect of JARID2 on EPCs proliferation, migration, and tube formation

EPCs were transfected with pc-JARID2 or si-JARID2 to observe the effect of JARID2. The negative controls (NC) was not transfected with pc-JARID2 or si-JARID2. We first used Western blotting to detect the protein expression level of JARID2 and found that JARID2 was markedly upregulated in the pc-JARID 2 group and downregulated in the si-JARID 2 group (Fig 3A). In addition, after evaluation by RT-qPCR, the quantitative data showed that miR-155 was significantly downregulated in the pc-JARID2 group, While in si-JARID2 group, the opposite trend was observed (Fig 3B). This finding suggests that pc-JARID2 can increase the level of JARID2 in EPCs while reducing the expression of miR-155. In contrast, si-JARID2 decreased JARID2 expression and increased miR-155 expression in EPCs.

Fig 3. Effect of JARID2 on EPCs proliferation, migration, and tube formation.

Fig 3

(A) The expression level of JARID2 protein was detected by Western blot; (B) The expression of miR-155 was detected by RT-qPCR; (C) CCK-8 to detect cell proliferation activity; (D) Cell migration level was detected by Transwell; (E) Detection of cell tube formation ability; (F) The level of Ang-1 secretion was detected by ELISA; (G) Western blot was used to detect the protein expression of VEGF and MMP-2. *P<0.05, **P<0.01 vs. NC group; #P<0.05, and ##P<0.01.

By analyzing the resulting data from CCK-8, Transwell, and tube-forming assays, we learned that EPCs viability, migration, and tube formation were decreased in the pc-JARID2 group but increased in the si-JARID2 group (Fig 3C–3E). In addition, the ELISA and Western blot results of angiogenesis-related factors showed that the levels of Ang-1, VEGF and MMP-2 presented downward trend in the pc-JARID2 group but increased in the si-JARID2 group (Fig 3F and 3G). These results suggest that upregulation of JARID2 expression can inhibit the development of EPCs and the expression levels of the angiogenesis-related factors Ang-1, VEGF and MMP-2.

3.4 JARID2 was identified as a direct target of miR-155

We identified nine targets of miR-155 using StarBase (Fig 4A). We cotransfected JADIR2-WT/MUT and miR-155 mimic into 293T cells and found that the miR-155 mimic decreased the luciferase activity of JADIR2-WT in 293T cells but had no effects on JADIR2-MUT compared to the NC mimic group (Fig 4B). Inhibition of miR-155 markedly raised the level of JADIR2, while overexpression of miR-155 significantly reduced JADIR2 protein expression (Fig 4C). Altogether, it is known from that experimental data that miR-155 targeted JADIR2 genes.

Fig 4. JARID2 was identified as a direct target of miR-155.

Fig 4

(A) Sequence of binding sites of miR-155 and JARID2; (B) Dual luciferase reporter gene was used to detect the targeting relationship between miR-155 and JARID2; (C) JARID2 protein expression was detected by Western blot. *P<0.05, **P<0.01, vs. miR-NC mimic or NC group.

3.5 Overexpression JARID2 weakened the promotion effect of miR-155 mimic on EPC proliferation, migration and tube formation

MiR-155 mimics and pc-JARID2 were simultaneously transfected into EPCs, with NC mimics and pc-NC as the respective negative controls. The negative controls (NC) was not transfected with miR-155 and JARID2. RT-qPCR results showed that transfection of miR-155 mimics alone promoted the expression of miR-155 and inhibited the expression of JARID2, while transfection of pc-JARID2 alone had the opposite result. In addition, when miR-155 mimics was co-transfected with pc-JARID2, the effect of miR-155 mimics was weakened (Fig 5A and 5B).

Fig 5. Overexpression JARID2 weakened the promotion effect of miR-155 mimic on EPC proliferation, migration and tube formation.

Fig 5

(A) The expression of miR-155 was detected by RT-qPCR; (B) The expression level of JARID2 mRNA was detected by RT-qPCR; (C)CCK-8 was used to detect the cell proliferation activity; (D) Transwell detection of cell migration level; (E)Detection of cell tube forming ability; (F) Detection of the secretion level of Ang-1 by ELISA; (G) Western blot was used to detect the protein expression of VEGF and MMP-2. *P<0.05, **P<0.01, and ***P<0.001 vs. NC group; #P<0.05, ##P<0.01, and ###P<0.001.

By analyzing the resulting data from CCK-8, Transwell, and tube-forming assays, we learned that the miR-155 mimics+pc-NC group promoted the proliferative activity, migration, and tube formation of EPCs, while the NC mimics +pc-JARID2 group decreased the proliferative activity, migration, and tube formation of EPCs compared with the NC group. However, the miR-155 mimics+pc-JARID2 group reversed the effects of miR-155 mimics+pc-NC and NC mimics+pc-JARID2 groups on EPCs viability, migration, and tube formation (Fig 5C–5E). In addition, the results of ELISA and Western blot detection of angiogenesis related factors showed that compared with NC group, miR-155 mimics+pc-NC group increased the secretion level of Ang-1 and the levels of VEGF and MMP-2 in EPCs. NC mimics+pc-JARID2 decreased the secretion of Ang-1 and the levels of VEGF and MMP-2 in EPCs. However, the miR-155 mimics+pc-JARID2 group reversed the effects of the miR-155 mimics+pc-NC group and the NC mimics+pc-JARID2 group on Ang-1 secretion levels and VEGF and MMP-2 protein expression levels in EPCs (Fig 5F and 5G).

3.6 Silencing JARID2 weakened the inhibitory effect of miR-155 inhibitor on EPC proliferation, migration and tube formation

MiR-155 inhibitor and si-JARID2 were simultaneously transfected into EPCs, with NC inhibitor and si-NC as respective negative controls. The negative controls (NC) was not transfected with miR-155 and JARID2. After evaluation by RT-qPCR, the quantitative data showed that the level of miR-155 in the miR-155 inhibitor + si-NC group showed a lower trend than that in the NC group, but the JARID2 mRNA was higher. The level of miR-155 showed a clear upward trend in the NC inhibitor+si-JARID2 group, but the JARID2 mRNA level decreased. The level of miR-155 and JARID2 in the miR-155 inhibitor+si-NC group and NC inhibitor + si-JARID2 group were reverse in that miR-155 inhibitor+si-JARID2 group effect of expression level (Fig 6A and 6B).

Fig 6. Silencing JARID2 weakened the inhibitory effect of miR-155 inhibitor on EPC proliferation, migration and tube formation.

Fig 6

(A) The expression of miR-155 was detected by RT-qPCR; (B) The expression level of JARID2 mRNA was detected by RT-qPCR; (C) CCK-8 was used to detect the cell proliferation activity; (D) Transwell detection of cell migration level; (E) Detection of cell tube forming ability; (F) Detection of the secretion level of Ang-1 by ELISA; (G) Western blot was used to detect the protein expression of VEGF and MMP-2. *P<0.05, **P<0.01, and ***P<0.001 vs. NC group; #P<0.05, ##P<0.01, and ###P<0.001.

We further revealed that miR-155 affects EPCs viability, migration, and tube formation through JARID2. The CCK-8, Transwell and tube formation assays showed that compared with the NC group, the miR-155 inhibitor +si-NC group showed reduced EPCs activity, migration and tube formation ability and the NC inhibitor + si-JARID2 group showed increased EPCs activity, migration and tube formation capacity. The miR-155 inhibitor + si-JARID2 group reversed the effects of the miR-155 inhibitor+si-NC group and the NC inhibitor + si-JARID2 group on EPCs viability, migration, and tube formation ability (Fig 6C–6E). In addition, the results of ELISA and Western blot detection of angiogenesis related factors showed that compared with the NC group, the miR-155 inhibitor+si-NC group reduced the secretion level of Ang-1 and the levels of VEGF and MMP-2 in EPCs. The NC inhibitor+si-JARID2 group increased the secretion of Ang-1 and expression of VEGF and MMP-2 proteins in EPCs. However, the miR-155 inhibitor+si-JARID2 group reversed the effects of the miR-155 inhibitor+si-NC group and the NC inhibitor+si-JARID2 group on the secretion level of Ang-1 and the levels of VEGF and MMP-2 in EPCs (Fig 6F and 6G).

3.7 Effect of EPCs transplantation on parenchymal lung volume, diaphragm surface area, and alveolar number in mice

To assess the effect of EPCs transplantation on the lung histomorphology, we transfected EPCs with miR-155 mimics and pc-JARID2 simultaneously, NC mimics and pc-NC were negative controls for each, and NC was EPCs without transfection with miR-155 mimics or pc-JARID2. EPCs from each group were transplanted into mice by tail vein injection, and the morphology of lung tissue was analyzed after 4 days. Compared with the NC group, the lung parenchyma volume, the septal surface area and the total number of alveoli were significantly increased in the miR-155 mimics+pc-NC EPCs group and decreased in the NC mimics+pc-JARID2 EPCs group. However, the miR-155 mimics+pc-JARID2 in the EPCs group reversed this phenomenon (Fig 7A–7C).

Fig 7. Effect of EPCs transplantation on parenchymal lung volume, diaphragm surface area, and alveolar number in mice.

Fig 7

(A) Mouse parenchymal lung volume; (B) Diaphragm surface area; (C) Total alveolar count. *P<0.05 vs. NC group; #P<0.05 compared with the transfection group.

3.8 Effect of EPCs transplantation on the number of pulmonary endothelial cells in mice

To further evaluate the effect of EPC transplantation on pulmonary endothelial cell proliferation. The results showed that compared with the control group, the number of endothelial cells increased in the miR-155 mimics+pc-NC EPC group, decreased in the NC mimics+pc-JARID2 EPC group, and reversed this phenomenon in the miR-155 mimics+pc-JARID2 EPC group (Fig 8A and 8B).

Fig 8. Effect of EPCs transplantation on the number of pulmonary endothelial cells in mice.

Fig 8

(A) Partial representative lung immunofluorescence; (B) Percentage of endothelial cell proliferation. *P<0.05, compared with NC group; #P<0.05.

4 Discussion

CLG is a confusing mechanism[28]. In humans, recent studies have shown that CLG may occur after pneumonectomy, although the timing may be several months to several years [29]. Compared with humans, pneumonectomy in small experimental animals results in CLG with complete recovery of lung volume [30]. A key factor in this regeneration is pulmonary angiogenesis during the formation of new alveoli. It is well known that EPCs has unique functions in angiogenesis as precursors of endothelial cells (ECs) [31,32]. These cells have the ability to differentiate and secrete cytokines to participate in angiogenesis [14]. In addition, CD34+ EPCs have been shown to contribute to pulmonary angiogenesis and transform into resident ECs during CLG [10]. Therefore, the results of all these studies point to a possible mechanism between CD34+ endothelial progenitor cells and lung compensatory growth. In this study, we found that EPCs transplantation increased the parenchymal lung volume, total alveolar number, septal surface area and the number of pulmonary endothelial cells, thereby promoting CLG after pneumonectomy in mice. These results indicate that activation of the biological function of EPCs can promote CLG. To explore the molecular mechanisms regulating the biological functions of EPCs, we carried out further studies.

MicroRNAs are small noncoding RNAs that they can silence or degrade mRNA, and then metabolize and degrade mRNA in biological processes, regulation of death. Moreover, they have unique functions in the regulation of cell migration, proliferation, apoptosis, and tube formation [33]. According to a large number of literatures, MiR-155 is a newly discovered miRNA, which has biological activities including lymphocyte activation, immune cell regulation, and microglial stimulation [34,35], and it is upregulated in a variety of diseases [3639]. We also know from a recent report that miR-155 has a significant function in promoting tumor angiogenesis by inducing the downregulation of von Hippel-Lindau (VHL). Moreover, knockout of miR-155 inhibits physiological function of human umbilical vein endothelial cells (HUVECs) [40], as well as a similar situation was found in human retinal vascular endothelial cells (HRMECs) [41]. Hence, the content of this study is mainly to describe the biological behavior of the EPCs. It is found that up regulation of miR-155 may promote the EPCs. However, down-regulation of miR-155 significantly inhibited the physiological function of EPCs. These results indicate that the mechanism of action needs to be further investigated. Studies have shown that miR-155 targets JARID2 and has unique functions in cell migration and tube formation.

JARID2 is a DNA-binding Jumonji protein involved in the negative regulation of cell growth [42]. Silencing JARID2 promotes the proliferation and differentiation of normal CD34+ cells[19], while amplification of JARID2 in HUVECs can lead to defective tube formation, indicating its inhibitory role in angiogenesis [43]. Furthermore, silencing JARID2 can enhance the viability of human cord blood and bone marrow-derived CD34+ cells and act as a novel regulator with a critical role in hematopoietic stem and progenitor cell (HSPC) function [44]. However, the relationship between JARID2 and miR-155 has rarely been discussed. After summarizing and analyzing the experimental data, we learned that miR-155 can target JARID2 based on software predictions and literature studies. Then, We found that down-regulation of miR-155 can increase the level of JARID2, and the amplification of JARID2 can reverse the promotion of physiological activities of EPCs. Our study found that miR-155 affected the expression of JARID2 protein, and JARID2 also affected the expression of miR-155. Studies have shown that JARID2 can play a key role as a cofactor in the cross-talk between histone modification and PRC2 activity [45]. Therefore, we speculate that JARID2 may mediate the posttranslational modification of a certain protein, thereby indirectly affecting the expression of miR-155.

At present, there are few reports about miR-155 in CLG disease. Through the analysis of experimental results in vitro, it is known that miR-155 regulates EPCs proliferation, migration and tube formation through JARID2. Then, in vivo experiments found that miR-155 has a unique function in promoting CLG disease. In addition, H&E staining and immunofluorescence analysis showed that EPCs transfected with miR-155 increased the volume of lung parenchyma, the total number of alveoli and the surface area of septum, and significantly increased the number of pulmonary endothelial cells, while the simultaneous overexpression of miR-155 and JARID2 reversed this trend. The possible mechanism of CLG is that miR-155 promotes CLG by regulating JARID2, and then affects the physiological function of EPCs.

5 Conclusion

In conclusion, our study reveals a novel role of miR-155 in the activation of EPCs and the promotion of CLG and provides important theoretical support for revealing the mechanism of puzzling CLG, which targets JARID2 to regulate EPCs proliferation, migration and tube formation.

Supporting information

S1 Raw images

(PDF)

pone.0296671.s001.pdf (277.6KB, pdf)
S1 Raw data

(ZIP)

pone.0296671.s002.zip (30.6MB, zip)
S2 Raw data

(ZIP)

pone.0296671.s003.zip (65.3MB, zip)
S3 Raw data

(ZIP)

pone.0296671.s004.zip (66.4MB, zip)
S4 Raw data

(ZIP)

pone.0296671.s005.zip (1.6MB, zip)
S5 Raw data

(ZIP)

pone.0296671.s006.zip (85.7MB, zip)
S6 Raw data

(ZIP)

pone.0296671.s007.zip (84.3MB, zip)
S7 Raw data

(ZIP)

pone.0296671.s008.zip (20.7KB, zip)
S8 Raw data

(ZIP)

pone.0296671.s009.zip (4.7MB, zip)

Data Availability

I have uploaded my data to the figshare database and below is a link to the data. link: https://figshare.com/s/cbde4268cf2ae018b832.

Funding Statement

This study was supported by Yunnan Provincial Science and Technology Department-Kunming Medical University (Grant No.202201AY070001-137); Joint Special Fund for Applied Basic Research of Yunnan Provincial Science and Technology Department-Kunming Medical University (No. 202101AY070001-170, No. 202301AY070001-085).

References

  • 1.Hsia C.C., Comparative analysis of the mechanical signals in lung development and compensatory growth. Cell Tissue Res, 2017. 367(3): p. 687–705. doi: 10.1007/s00441-016-2558-8 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Butler J.P., et al., Evidence for adult lung growth in humans. The New England journal of medicine, 2012. 367(3): p. 244–247. doi: 10.1056/NEJMoa1203983 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Gibney B.C., et al., Mechanostructural adaptations preceding postpneumonectomy lung growth. Exp Lung Res, 2012. 38(8): p. 396–405. doi: 10.3109/01902148.2012.715364 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Matsumoto K., et al., Keratinocyte growth factor accelerates compensatory growth in the remaining lung after trilobectomy in rats. J Thorac Cardiovasc Surg, 2009. 137(6): p. 1499–507. doi: 10.1016/j.jtcvs.2008.11.037 [DOI] [PubMed] [Google Scholar]
  • 5.Dao D.T., et al., Vascular Endothelial Growth Factor Enhances Compensatory Lung Growth in Piglets. Surgery, 2018. 164(6): p. 1279–1286. doi: 10.1016/j.surg.2018.07.003 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Hsia C.C., Lessons from a canine model of compensatory lung growth. Curr Top Dev Biol, 2004. 64: p. 17–32. doi: 10.1016/S0070-2153(04)64002-6 [DOI] [PubMed] [Google Scholar]
  • 7.Serý Z., Keprt E., and Obrucník M., Morphometric analysis of late adaptation of the residual lung following pneumonectomy in young and adult rabbits. J Thorac Cardiovasc Surg, 1969. 57(4): p. 549–57. [PubMed] [Google Scholar]
  • 8.McBride J.T., Lung volumes after an increase in lung distension in pneumonectomized ferrets. J Appl Physiol (1985), 1989. 67(4): p. 1418–21. doi: 10.1152/jappl.1989.67.4.1418 [DOI] [PubMed] [Google Scholar]
  • 9.Ackermann M., et al., Sprouting and intussusceptive angiogenesis in postpneumonectomy lung growth: mechanisms of alveolar neovascularization. Angiogenesis, 2014. 17(3): p. 541–51. doi: 10.1007/s10456-013-9399-9 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Chamoto K., et al., CD34+ progenitor to endothelial cell transition in post-pneumonectomy angiogenesis. Am J Respir Cell Mol Biol, 2012. 46(3): p. 283–9. doi: 10.1165/rcmb.2011-0249OC [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Ozkok A. and Yildiz A., Endothelial Progenitor Cells and Kidney Diseases. Kidney Blood Press Res, 2018. 43(3): p. 701–718. doi: 10.1159/000489745 [DOI] [PubMed] [Google Scholar]
  • 12.Kolesnichenko O.A., et al., Therapeutic Potential of Endothelial Progenitor Cells in Pulmonary Diseases. Am J Respir Cell Mol Biol, 2021. 65(5): p. 473–488. doi: 10.1165/rcmb.2021-0152TR [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Yang X., et al., Down-regulation of miR-361-5p promotes the viability, migration and tube formation of endothelial progenitor cells via targeting FGF1. Bioscience reports, 2020. 40(10): p. BSR20200557. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Kong Z., et al., MicroRNA-126 promotes endothelial progenitor cell proliferation and migration ability via the Notch pathway. Cardiovascular diagnosis and therapy, 2020. 10(3): p. 490–499. doi: 10.21037/cdt-20-178 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Hartmann J.U., et al., MicroRNA-143 targets ERK5 in granulopoiesis and predicts outcome of patients with acute myeloid leukemia. Cell Death Dis, 2018. 9(8): p. 814. doi: 10.1038/s41419-018-0837-x [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Shaik S., et al., microRNA Sequencing of CD34+ Sorted Adipose Stem Cells Undergoing Endotheliogenesis. Stem Cells Dev, 2021. 30(5): p. 265–288. doi: 10.1089/scd.2020.0173 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Mahdloo T., et al., Up-regulation of miR-155 potentiates CD34+ CML stem/progenitor cells to escape from the growth-inhibitory effects of TGF-ß1 and BMP signaling. Excli j, 2021. 20: p. 748–763. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Correia de Sousa M., et al., Deciphering miRNAs’ Action through miRNA Editing. Int J Mol Sci, 2019. 20(24). doi: 10.3390/ijms20246249 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Norfo R., et al., miRNA-mRNA integrative analysis in primary myelofibrosis CD34+ cells: role of miR-155/JARID2 axis in abnormal megakaryopoiesis. Blood, 2014. 124(13): p. e21–32. doi: 10.1182/blood-2013-12-544197 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Bolisetty M.T., et al., Reticuloendotheliosis virus strain T induces miR-155, which targets JARID2 and promotes cell survival. J Virol, 2009. 83(23): p. 12009–17. doi: 10.1128/JVI.01182-09 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Xu M., et al., MiR-155 contributes to Th17 cells differentiation in dextran sulfate sodium (DSS)-induced colitis mice via Jarid2. Biochem Biophys Res Commun, 2017. 488(1): p. 6–14. doi: 10.1016/j.bbrc.2017.04.143 [DOI] [PubMed] [Google Scholar]
  • 22.Escobar T.M., et al., miR-155 activates cytokine gene expression in Th17 cells by regulating the DNA-binding protein Jarid2 to relieve polycomb-mediated repression. Immunity, 2014. 40(6): p. 865–79. doi: 10.1016/j.immuni.2014.03.014 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Jiang Y., Chen Y., and Chen Y., Knockdown of JARID2 inhibits the viability and migration of placenta trophoblast cells in preeclampsia. Mol Med Rep, 2017. 16(3): p. 3594–3599. doi: 10.3892/mmr.2017.7011 [DOI] [PubMed] [Google Scholar]
  • 24.Wang X., et al., Jarid2 enhances the progression of bladder cancer through regulating PTEN/AKT signaling. Life Sci, 2019. 230: p. 162–168. doi: 10.1016/j.lfs.2019.05.053 [DOI] [PubMed] [Google Scholar]
  • 25.van Beijnum J, Rousch M, Castermans K, van der Linden E, Griffioen A. (2008). Isolation of endothelial cells from fresh tissues. Nat Protoc 3:1085–1091. doi: 10.1038/nprot.2008.71 [DOI] [PubMed] [Google Scholar]
  • 26.Mühlfeld C. and Ochs M., Quantitative microscopy of the lung: a problem-based approach. Part 2: stereological parameters and study designs in various diseases of the respiratory tract. Am J Physiol Lung Cell Mol Physiol, 2013. 305(3): p. L205–21. doi: 10.1152/ajplung.00427.2012 [DOI] [PubMed] [Google Scholar]
  • 27.Ochs M. and Mühlfeld C., Quantitative microscopy of the lung: a problem-based approach. Part 1: basic principles of lung stereology. Am J Physiol Lung Cell Mol Physiol, 2013. 305(1): p. L15–22. doi: 10.1152/ajplung.00429.2012 [DOI] [PubMed] [Google Scholar]
  • 28.Mentzer S.J., The puzzling mechanism of compensatory lung growth. Stem cell investigation, 2018. 5: p. 8–8. doi: 10.21037/sci.2018.03.01 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Dao D.T., et al., Heparin impairs angiogenic signaling and compensatory lung growth after left pneumonectomy. Angiogenesis, 2018. 21(4): p. 837–848. doi: 10.1007/s10456-018-9628-3 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Tsikis S.T., et al., Direct thrombin inhibitors as alternatives to heparin to preserve lung growth and function in a murine model of compensatory lung growth. Sci Rep, 2022. 12(1): p. 21117. doi: 10.1038/s41598-022-25773-3 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Xia L.Z., et al., Factors Affecting the Re-Endothelialization of Endothelial Progenitor Cell. DNA Cell Biol, 2021. 40(7): p. 1009–1025. doi: 10.1089/dna.2021.0082 [DOI] [PubMed] [Google Scholar]
  • 32.Blum A., et al., Inhibition of endothelial Progenitor Cells Inhibition in the first 24 hours of an Acute Ischemic Cerebrovascular Event. Isr Med Assoc J, 2019. 21(2): p. 71–76. [PubMed] [Google Scholar]
  • 33.Sun L.L., et al., MiR-205 promotes endothelial progenitor cell angiogenesis and deep vein thrombosis recanalization and resolution by targeting PTEN to regulate Akt/autophagy pathway and MMP2 expression. J Cell Mol Med, 2019. 23(12): p. 8493–8504. doi: 10.1111/jcmm.14739 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Thai T.H., et al., Regulation of the germinal center response by microRNA-155. Science, 2007. 316(5824): p. 604–8. doi: 10.1126/science.1141229 [DOI] [PubMed] [Google Scholar]
  • 35.Rodriguez A., et al., Requirement of bic/microRNA-155 for normal immune function. Science, 2007. 316(5824): p. 608–11. doi: 10.1126/science.1139253 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Devier D.J., Lovera J.F., and Lukiw W.J., Increase in NF-κB-sensitive miRNA-146a and miRNA-155 in multiple sclerosis (MS) and pro-inflammatory neurodegeneration. Front Mol Neurosci, 2015. 8: p. 5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Lukiw W.J., et al., Common micro RNAs (miRNAs) target complement factor H (CFH) regulation in Alzheimer’s disease (AD) and in age-related macular degeneration (AMD). Int J Biochem Mol Biol, 2012. 3(1): p. 105–16. [PMC free article] [PubMed] [Google Scholar]
  • 38.Li Y.Y., et al., miRNA-155 upregulation and complement factor H deficits in Down’s syndrome. Neuroreport, 2012. 23(3): p. 168–73. doi: 10.1097/WNR.0b013e32834f4eb4 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Kutty R.K., et al., Inflammatory cytokines regulate microRNA-155 expression in human retinal pigment epithelial cells by activating JAK/STAT pathway. Biochem Biophys Res Commun, 2010. 402(2): p. 390–5. doi: 10.1016/j.bbrc.2010.10.042 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Kong W., et al., Upregulation of miRNA-155 promotes tumour angiogenesis by targeting VHL and is associated with poor prognosis and triple-negative breast cancer. Oncogene, 2014. 33(6): p. 679–89. doi: 10.1038/onc.2012.636 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Zhuang Z., et al., Down-regulation of microRNA-155 attenuates retinal neovascularization via the PI3K/Akt pathway . Molecular vision, 2015. 21: p. 1173–1184. [PMC free article] [PubMed] [Google Scholar]
  • 42.Toyoda M., Kojima M., and Takeuchi T., Jumonji is a nuclear protein that participates in the negative regulation of cell growth. Biochem Biophys Res Commun, 2000. 274(2): p. 332–6. doi: 10.1006/bbrc.2000.3138 [DOI] [PubMed] [Google Scholar]
  • 43.Singh B.N., et al., Etv2-miR-130a-Jarid2 cascade regulates vascular patterning during embryogenesis. PloS one, 2017. 12(12): p. e0189010-e0189010. doi: 10.1371/journal.pone.0189010 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.Kinkel S.A., et al., Jarid2 regulates hematopoietic stem cell function by acting with polycomb repressive complex 2. Blood, 2015. 125(12): p. 1890–1900. doi: 10.1182/blood-2014-10-603969 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45.Kasinath V., et al., JARID2 and AEBP2 regulate PRC2 in the presence of H2AK119ub1 and other histone modifications. Science, 2021. 371(6527). doi: 10.1126/science.abc3393 [DOI] [PMC free article] [PubMed] [Google Scholar]

Decision Letter 0

Zhijie Xu

7 Aug 2023

PONE-D-23-15191MiR-155 promotes compensatory lung growth by inhibiting JARID2 activation of CD34+ endothelial progenitor cellsPLOS ONE

Dear Dr. Wang,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Sep 21 2023 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Zhijie Xu

Academic Editor

PLOS ONE

Journal requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. To comply with PLOS ONE submissions requirements, in your Methods section, please provide additional information regarding the experiments involving animals and ensure you have included details on (1) methods of sacrifice, and (2) efforts to alleviate suffering.

3. Thank you for stating the following financial disclosure:

“This study was supported by the Regional Program of the National Natural Science Foundation of China (No. 81760423); Joint Special Fund for Applied Basic Research of Yunnan Provincial Science and Technology Department-Kunming Medical University (No. 202101AY070001-170).”

Please state what role the funders took in the study.  If the funders had no role, please state: "The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript."

If this statement is not correct you must amend it as needed.

Please include this amended Role of Funder statement in your cover letter; we will change the online submission form on your behalf.

4. In your Data Availability statement, you have not specified where the minimal data set underlying the results described in your manuscript can be found. PLOS defines a study's minimal data set as the underlying data used to reach the conclusions drawn in the manuscript and any additional data required to replicate the reported study findings in their entirety. All PLOS journals require that the minimal data set be made fully available. For more information about our data policy, please see http://journals.plos.org/plosone/s/data-availability.

Upon re-submitting your revised manuscript, please upload your study’s minimal underlying data set as either Supporting Information files or to a stable, public repository and include the relevant URLs, DOIs, or accession numbers within your revised cover letter. For a list of acceptable repositories, please see http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories. Any potentially identifying patient information must be fully anonymized.

Important: If there are ethical or legal restrictions to sharing your data publicly, please explain these restrictions in detail. Please see our guidelines for more information on what we consider unacceptable restrictions to publicly sharing data: http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions. Note that it is not acceptable for the authors to be the sole named individuals responsible for ensuring data access.

We will update your Data Availability statement to reflect the information you provide in your cover letter.

5. Your ethics statement should only appear in the Methods section of your manuscript. If your ethics statement is written in any section besides the Methods, please move it to the Methods section and delete it from any other section. Please ensure that your ethics statement is included in your manuscript, as the ethics statement entered into the online submission form will not be published alongside your manuscript.

6. PLOS ONE now requires that authors provide the original uncropped and unadjusted images underlying all blot or gel results reported in a submission’s figures or Supporting Information files. This policy and the journal’s other requirements for blot/gel reporting and figure preparation are described in detail at https://journals.plos.org/plosone/s/figures#loc-blot-and-gel-reporting-requirements and https://journals.plos.org/plosone/s/figures#loc-preparing-figures-from-image-files. When you submit your revised manuscript, please ensure that your figures adhere fully to these guidelines and provide the original underlying images for all blot or gel data reported in your submission. See the following link for instructions on providing the original image data: https://journals.plos.org/plosone/s/figures#loc-original-images-for-blots-and-gels.

In your cover letter, please note whether your blot/gel image data are in Supporting Information or posted at a public data repository, provide the repository URL if relevant, and provide specific details as to which raw blot/gel images, if any, are not available. Email us at plosone@plos.org if you have any questions.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: This article tells a very interesting story and has a clear scientific research idea. However, it still needs to be revised before publication. Specific comments are as follows:

1. The part of animal experiments needs to be supplemented.

2.In animal modeling experiments, the basis for selecting 4 days as the time point needs to be supplemented.

3.Negative control groups were added to the mimics and inhibitors when the transfection efficiency was detected.

4.It is necessary to increase the citation of literature in recent years.

Reviewer #2: Manuscript submitted by Weiwei Wang “MiR-155 promotes compensatory growth by inhibiting JARID2 activation of CD34+ endothelial progenitor cells” convincingly showed in vitro (cell-culture) and in-vivo (mice model) that miR-155 controls activation of CD34-endothelial progenitor cell that lid to neovascularization and pulmonary angiogenesis (compensatory lung growth (CLG)) by the direct targeting of JARID2.

The results presented on the figure 3, 5 and 6 showing that not only that amount of miR-155 effected expression of JARID2 protein but also amount of JARID2 protein effect expression level of miR-155. It is not clear for me why authors did not discuss the effect of JARID2 protein on the expression level of miR-155 in the manuscript

The titles of two chapters of result section looks confusing for me:

274 3.5 Amplification of JARID2 Reverses the Effect of miR-155 on EPCs

275 Proliferation, Migration, and Tube Formation

300 3.6 Silencing JARID2 Reverses the Effect of miR-155 on EPCs Proliferation,

301 Migration, and Tube Formation

I think authors should specialized which effect of miR-155 was reversed by amplification and which one was reversed by silencing of JARID2.

In conclusion I recommend the manuscript for publication at PlOS1 journal after authors will addressed my concerns.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2024 Feb 23;19(2):e0296671. doi: 10.1371/journal.pone.0296671.r002

Author response to Decision Letter 0


11 Oct 2023

Dear Editors and Reviewers:

Thank you for your letter and for the reviewer's comments concerning our manuscript entitled "MiR-155 promotes compensatory lung growth by inhibiting JARID2 activation of CD34+ endothelial progenitor cells". Those comments are all valuable and very helpful for revising and improving our paper, as well as the important guiding significance to our researches. We have studied comments carefully and have made correction which we hope meet with approval. Revised portion are marked in red in the paper. The main corrections in the paper and the responds to the reviewer's comments are as flowing:

Responds to the journal requirements:

1. Comment: Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

Response: I have checked PLOS ONE style templates according to the link you provided, and revised our manuscript one by one according to the style samples.

Changes in the text: Level Heading, Figure Citations.

2. Comment: To comply with PLOS ONE submissions requirements, in your Methods section, please provide additional information regarding the experiments involving animals and ensure you have included details on (1) methods of sacrifice, and (2) efforts to alleviate suffering.

Response: According to your request, I have added the methods of animal sacrifice and the efforts made to alleviate their suffering in the methods section.

Changes in the text: Page 9, lines 171-173, 180.

3. Comment: Please also state specifically the method of anesthesia.

Response: I have added specific anesthesia methods in the section of Materials and methods according to your requirements.

Changes in the text: Page 5, lines 94-95; Page 8, lines 166-167.

4. Comment: Thank you for stating the following financial disclosure: “This study was supported by the Regional Program of the National Natural Science Foundation of China (No. 81760423); Joint Special Fund for Applied Basic Research of Yunnan Provincial Science and Technology Department-Kunming Medical University(No. 202101AY070001-170).” Please state what role the funders took in the study. If the funders had no role, please state: "The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript." If this statement is not correct you must amend it as needed. Please include this amended Role of Funder statement in your cover letter; we will change the online submission form on your behalf.

Response: The funder is Weiwei Wang, the corresponding author of the fund applicant in this article. Weiwei Wang's role in the research has been elaborated in the author's contribution section, mainly in designing article ideas, reading and revising manuscripts.

Changes in the text: No changes are made in the text.

5. Comment: In your Data Availability statement, you have not specified where the minimal data set underlying the results described in your manuscript can be found. PLOS defines a study's minimal data set as the underlying data used to reach the conclusions drawn in the manuscript and any additional data required to replicate the reported study findings in their entirety. All PLOS journals require that the minimal data set be made fully available. For more information about our data policy, please see http://journals.plos.org/plosone/s/data-availability.

Upon re-submitting your revised manuscript, please upload your study’s minimal underlying data set as either Supporting Information files or to a stable, public repository and include the relevant URLs, DOIs, or accession numbers within your revised cover letter. For a list of acceptable repositories, please see http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories. Any potentially identifying patient information must be fully anonymized.

Important: If there are ethical or legal restrictions to sharing your data publicly, please explain these restrictions in detail. Please see our guidelines for more information on what we consider unacceptable restrictions to publicly sharing data: http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions. Note that it is not acceptable for the authors to be the sole named individuals responsible for ensuring data access.

We will update your Data Availability statement to reflect the information you provide in your cover letter.

Response: I've sorted out all the raw data for the article, but I'm not sure how to get it into the database. So I uploaded the original data at the " Supporting Information - Compressed/ZIP File Archive " position in the submission system.

Changes in the text: No changes are made in the text.

6. Comment: Your ethics statement should only appear in the Methods section of your manuscript. If your ethics statement is written in any section besides the Methods, please move it to the Methods section and delete it from any other section. Please ensure that your ethics statement is included in your manuscript, as the ethics statement entered into the online submission form will not be published alongside your manuscript.

Response: I've moved the ethics statement to the methods section as you requested.

Changes in the text: Page 9, lines 182-184.

7. Comment: PLOS ONE now requires that authors provide the original uncropped and unadjusted images underlying all blot or gel results reported in a submission’s figures or Supporting Information files. This policy and the journal’s other requirements for blot/gel reporting and figure preparation are described in detail at https://journals.plos.org/plosone/s/figures#loc-blot-and-gel-reporting-requirements and https://journals.plos.org/plosone/s/figures#loc-preparing-figures-from-image-files. When you submit your revised manuscript, please ensure that your figures adhere fully to these guidelines and provide the original underlying images for all blot or gel data reported in your submission. See the following link for instructions on providing the original image data:

https://journals.plos.org/plosone/s/figures#loc-original-images-for-blots-and-gels.

In your cover letter, please note whether your blot/gel image data are in Supporting Information or posted at a public data repository, provide the repository URL if relevant, and provide specific details as to which raw blot/gel images, if any, are not available. Email us at plosone@plos.org if you have any questions.

Response: I have sorted out all the uncropped blot/gel images in the manuscript according to your requirements and uploaded them through the system named file " S1_raw_images".

Changes in the text: No changes are made in the text.

Responds to the reviewer’s comments:

Reviewer 1

1. Comment: The part of animal experiments needs to be supplemented.

Response: Thanks for your comment on our paper. I have supplemented the content of animal experiments in more detail according to your request.

Changes in the text: Page 8, lines 166-170; Page 9, lines 171-173.

2. Comment: In animal modeling experiments, the basis for selecting 4 days as the time point needs to be supplemented.

Response: I have added in the manuscript that the basis for choosing 4 days as the time point is because this is the most active lung growth point.

Changes in the text: Page 9, lines 180-181.

3. Comment: Negative control groups were added to the mimics and inhibitors when the transfection efficiency was detected.

Response: Taking into account your comments, we have added a negative control group of mimics and inhibitors in the transfection efficiency detection experiment of miR-155 mimics and inhibitors.

Changes in the text: Figure 2A.

4. Comment: It is necessary to increase the citation of literature in recent years.

Response: Considering the reviewer's suggestion, I have replaced and updated some of the literature in the manuscript with some recent literature.

Changes in the text: Page 22, lines 444-445,448-452,455-466,469-470,484; Page 23, lines 485, 509-514.

Reviewer 2

1. Comment: The results presented on the figure 3, 5 and 6 showing that not only that amount of miR-155 effected expression of JARID2 protein but also amount of JARID2 protein effect expression level of miR-155. It is not clear for me why authors did not discuss the effect of JARID2 protein on the expression level of miR-155 in the manuscript.

Response: Taking into account your comment, we have supplemented the discussion of this result in the manuscript. Reviewing the literature, we learned that JARID2 can be used as a cofactor to mediate histone modification, so we speculate that JARID2 may mediate the post-translational modification of a protein and thus indirectly affect the expression of miR-155.

Changes in the text: Page 19, lines 396-400; Page 20, lines 401-404.

2. Comment: The titles of two chapters of result section looks confusing for me:

274 3.5 Amplification of JARID2 Reverses the Effect of miR-155 on EPCs

275 Proliferation, Migration, and Tube Formation

300 3.6 Silencing JARID2 Reverses the Effect of miR-155 on EPCs Proliferation,

301 Migration, and Tube Formation

Response: The contents of these two sections are actually intended to show that miR-155 affects EPC proliferation, migration and tube formation ability through JARID2. Therefore, we designed the experiment of overexpression and silence of JARID2 to observe the influence of JARID2 protein changes on the action of miR-155. It may be true that the expression of these two subheadings is not so clear that you are confused, so we have re-written these two subheadings as follows:

3.5 Overexpression JARID2 weakened the promotion effect of miR-155 mimic on EPC proliferation, migration and tube formation

3.6 Silencing JARID2 weakened the inhibitory effect of miR-155 inhibitor on EPC proliferation, migration and tube formation

Changes in the text: Page 14, lines 278-280; Page 15, lines 302-304.

3. Comment: I think authors should specialized which effect of miR-155 was reversed by amplification and which one was reversed by silencing of JARID2.

Response: Our results have shown that both overexpression and silencing of JARID2 affect the effects of miR-155 on EPC proliferation, migration and tube formation. So we have to supplement the experiments that need to be studied in your opinion.

Changes in the text: No changes are made in the text.

Attachment

Submitted filename: Response to Reviewers.docx

pone.0296671.s010.docx (22.2KB, docx)

Decision Letter 1

Zhijie Xu

18 Dec 2023

MiR-155 promotes compensatory lung growth by inhibiting JARID2 activation of CD34+ endothelial progenitor cells

PONE-D-23-15191R1

Dear Dr. Wang,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Zhijie Xu

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #2: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #2: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #2: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #2: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #2: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #2: I am satisfied with author's manuscript corrections. My suggestions were addressed I recommend the manuscript for publication

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #2: No

**********

Acceptance letter

Zhijie Xu

15 Feb 2024

PONE-D-23-15191R1

PLOS ONE

Dear Dr. Wang,

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now being handed over to our production team.

At this stage, our production department will prepare your paper for publication. This includes ensuring the following:

* All references, tables, and figures are properly cited

* All relevant supporting information is included in the manuscript submission,

* There are no issues that prevent the paper from being properly typeset

If revisions are needed, the production department will contact you directly to resolve them. If no revisions are needed, you will receive an email when the publication date has been set. At this time, we do not offer pre-publication proofs to authors during production of the accepted work. Please keep in mind that we are working through a large volume of accepted articles, so please give us a few weeks to review your paper and let you know the next and final steps.

Lastly, if your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

If we can help with anything else, please email us at customercare@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Prof. Zhijie Xu

Academic Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 Raw images

    (PDF)

    pone.0296671.s001.pdf (277.6KB, pdf)
    S1 Raw data

    (ZIP)

    pone.0296671.s002.zip (30.6MB, zip)
    S2 Raw data

    (ZIP)

    pone.0296671.s003.zip (65.3MB, zip)
    S3 Raw data

    (ZIP)

    pone.0296671.s004.zip (66.4MB, zip)
    S4 Raw data

    (ZIP)

    pone.0296671.s005.zip (1.6MB, zip)
    S5 Raw data

    (ZIP)

    pone.0296671.s006.zip (85.7MB, zip)
    S6 Raw data

    (ZIP)

    pone.0296671.s007.zip (84.3MB, zip)
    S7 Raw data

    (ZIP)

    pone.0296671.s008.zip (20.7KB, zip)
    S8 Raw data

    (ZIP)

    pone.0296671.s009.zip (4.7MB, zip)
    Attachment

    Submitted filename: Response to Reviewers.docx

    pone.0296671.s010.docx (22.2KB, docx)

    Data Availability Statement

    I have uploaded my data to the figshare database and below is a link to the data. link: https://figshare.com/s/cbde4268cf2ae018b832.


    Articles from PLOS ONE are provided here courtesy of PLOS

    RESOURCES